Business
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atea
About this update from Atea Pharmaceuticals, Inc.
[{"type":"text","content":"Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment is needed for CYP3A substrates or for drugs that are sensitive substrates of efflux and hepatic uptake transporters when co-administrated with bemnifosbuvir. CYP3A is an enzyme that metabolizes many classes of prescribed medicines and medicinal supplements, and efflux/hepatic uptake transporters regulate cellular trafficking of many drugs that are commonly prescribed to patients that are at high risk for severe COVID-19. These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI), which took place February 19-22, 2023 in Seattle, Washington. Bemnifosbuvir is an investigational orally administered, direct-acting antiviral. It is being evaluated in the global SUNRISE-3 Phase 3 registrational trial for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression to hospitalization and death. “A key limitation of currently available treatments for COVID-19 is drug-drug interactions, especially for elderly and immunocompromised patients,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “We are pleased that the clinical data presented at CROI demonstrate that bemnifosbuvir may be co-administered without drug-drug interactions with commonly prescribed therapeutics that patients may be taking for other conditions. In the Phase 3 SUNRISE-3 trial, we are targeting the most vulnerable patient populations who are at the greatest risk for disease progression to severe COVID-19 or mortality, and for whom there are currently the fewest treatment options.” Poster Number: 512Title: No Dose Adjustments for CYP3A4 Substrates When Co-Administered with Bemnifosbuvir Results from a Phase 1, open-label, drug-drug interaction (DDI) study suggest that no dose adjustments are needed when bemnifosbuvir is co-administered with drugs that are substrates of CYP3A4. In the study, bemnifosbuvir was administered with midazolam (MDZ; used as a sensitive CYP3A4 index drug) in 24 healthy ...